The Company
KreLo GmbH was founded in April 2004 and is located at Biotechnology Center (TFU) in Ulm/Germany
Managing Director is Prof. Dr. med. Ulrich Loos (CV).
Authorized officer is Dr. rer. biol. Claudia Frank.
Aims are research & development of in vitro diagnostic kits, especially for autoimmune diseases.
The first test for the direct detection of autoantibodies by a novel detection technology (bridge assay) was successfully developed for autoantibodies causing Graves’ Disease and will be commercially provided beginning 2008.
Further Services:
- Development of LIA (luminescent immuno assay)
- Establishment of production cell lines stably expressing recombinant proteins.
- Cloning of custom sequences for expression of recombinant proteins
- Construction of custom based reporter gene constructs